Company Analysis

Alto Neuroscience Inc. (ANRO)

NYSE: ANRO · Pharmaceutical Preparations · Mountain View, CA · filing with the SEC since 2023
Grade5.2
◀ Past 4.6● Present 4.5▶ Future 6.3
7 est.

Who runs Alto Neuroscience Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Etkin Amit
PRESIDENT AND CEO. First filing Feb 2024, latest May 15, 2026, 1 filing in all.
Officers reporting now
4
of 10 people with a filing in the last fifteen months
Directors reporting now
6
13 people on the record since 2024
Officerssales are open-market, Oct 5, 2025 to Oct 5, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Smith Nicholas ConradPRESIDENT AND CFOFeb 2024Oct 5, 20263 · $3.6M
Etkin AmitPRESIDENT AND CEOFeb 2024May 15, 2026none
Hanley Jr. Michael ConickCHIEF OPERATING OFFICERMay 2024Feb 13, 2026none
Savitz AdamCHIEF MEDICAL OFFICERFeb 2024Feb 13, 2026none
Directorssales are open-market, Oct 5, 2025 to Oct 5, 2026
NameRoleFirst filingLatest filingSales, 12 months
Miller Andrew CraigdirectorMay 2026May 29, 2026none
Cox Christopher NixondirectorFeb 2024May 14, 2026none
Dreyfus AndrewdirectorFeb 2024May 14, 2026none
Manji HusseinidirectorFeb 2024May 14, 2026none
Sanchez RamirodirectorAug 2025May 14, 2026none
York GwilldirectorFeb 2024May 14, 2026none
Earlier names on the record10, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton ANRO · research, not advice